...
首页> 外文期刊>Nutrition, metabolism, and cardiovascular diseases: NMCD >Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials
【24h】

Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials

机译:预防和治疗先兆子痫的口服抗氧化疗法:随机对照试验的荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

AimsTo determine whether oral antioxidant therapies, of various types and doses, are able to prevent or treat women with preeclampsia. Data synthesisThe following databases were searched: MEDLINE, CENTRAL, LILACS, and Web of Science. Inclusion criteria were: a) randomized clinical trials; b) oral antioxidant supplementation; c) study in pregnant women; d) control group, treated or not with placebo. Papers were excluded if they evaluated antioxidant nutrient supplementation associated with other non-antioxidant therapies. Data were extracted and the risk of bias of each study was assessed. Heterogeneity was analyzed using the Cochran Q test, and I2 statistics and pre-specified sensitivity analyses were performed. Meta-analyses were conducted on prevention and treatment studies, separately. The primary outcome was the incidence of preeclampsia in prevention trials, and of perinatal death in treatment trials. Twenty-nine studies were included in the analysis, 19 for prevention and 10 for treatment. The antioxidants used in these studies were vitamins C and E, selenium,l-arginine, allicin, lycopene and coenzyme Q10, none of which showed beneficial effects on the prevention of preeclampsia (RR: 0.89, CI 95%: [0.79–1.02], P?=?0.09; I2?=?39%, P?=?0.04) and other outcomes. The antioxidants used in the treatment studies were vitamins C and E,N-acetylcysteine,l-arginine, and resveratrol. A beneficial effect was found in intrauterine growth restriction. ConclusionsAntioxidant therapy had no effects in the prevention of preeclampsia but did show beneficial effects in intrauterine growth restriction, when used in the treatment of this condition.
机译:Aimsto确定口腔抗氧化疗法是否有各种类型和剂量,能够预防或治疗患有先兆子痫的妇女。在搜索数据库之后的数据综合性:Medline,Central,Lilacs和Science Web。纳入标准是:a)随机临床试验; b)口服抗氧化剂补充剂; c)孕妇的研究; d)对照组,治疗与安慰剂。如果他们评估与其他非抗氧化疗法相关的抗氧化营养补充剂,则排除纸张。提取数据并评估每项研究的偏差风险。使用Cochran Q测试分析异质性,并进行I2统计和预先指定的敏感性分析。在预防和治疗研究中进行了荟萃分析。主要结果是预防试验中预坦克敏的发病率,以及治疗试验中的围产期死亡。分析中包含二十九项研究,19例预防和10种治疗。这些研究中使用的抗氧化剂是维生素C和E,硒,L-精氨酸,含有丙蛋白,番茄红素和辅酶Q10,其中没有任何对预防预防预防胰岛素(RR:0.89,CI 95%:[0.79-1.02]。 ,p?= 0.09; I2?=?39%,p?=?0.04)和其他结果。治疗研究中使用的抗氧化剂是维生素C和E,N-乙酰半胱氨酸,L-精氨酸和白藜芦醇。在宫内生长限制中发现了有益效果。结论在预防预坦克敏的情况下没有影响,但在治疗这种情况下使用时表现出宫内生长限制的有益效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号